Scholarlink

<p><i>KMT2A</i>-altered acute myeloid leukemia (AML) comprises rearrangements (<i>KMT2A</i>-r), partial tandem duplications (<i>KMT2A</i>-PTD), and dual alterations (<i>KMT2A</i>-r/PTD). In this study of 125 patients, these subgroups exhibited distinct molecular profiles: <i>KMT2A</i>-r cases were enriched in RAS pathway mutations, whereas <i>KMT2A</i>-PTD showed a higher burden of epigenetic alterations. Although overall survival (OS) and event-free survival (EFS) did not differ significantly between subgroups, prognosis was strongly influenced by fusion partners. <i>MLLT3/ELL</i>-rearranged cases showed superior outcomes, but concurrent <i>KMT2A</i>-PTD abrogated this survival advantage, <i>AFDN</i> and other fusions showed poor outcomes. We therefore propose a revised three-tier risk model integrating fusion partner and PTD status, which significantly stratified patient outcomes. The intermediate-risk group (<i>MLLT3/ELL</i> without PTD) had a 3-year OS of 78.1%, compared to 50.5% in the high-risk group (all PTD), and 34.9% in the very high-risk group (other <i>KMT2A</i>-r) (<i>P</i> = 0.044). For EFS, the rates were 71.0%, 40.1%, and 24.9%, respectively (<i>P</i> = 0.003). Allogeneic hematopoietic cell transplantation significantly improved survival, with 3-year OS rates of 75.2% in transplant recipients versus 22.5% in non-transplanted patients (<i>P</i> &lt; 0.001), particularly in high-risk groups and when performed in first complete remission. These findings support the use of molecularly guided, risk-adapted therapy in <i>KMT2A</i>-altered AML.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

KMT2A alterations in acute myeloid leukemia: a proposed genetic risk model and transplantation outcomes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月21日

查看全文
  • Li Chen,
  • Jianfeng Li,
  • Yongmei Zhu,
  • Xiangqin Weng,
  • Yuting Huang,
  • Lingling Zhao,
  • Guang Yang,
  • Ting Huang,
  • Ran An,
  • Zhiyin Liu,
  • Xiaoqian Xu,
  • Yubao Chen,
  • Qiuhua Huang,
  • Kankan Wang,
  • Sujiang Zhang

摘要

KMT2A-altered acute myeloid leukemia (AML) comprises rearrangements (KMT2A-r), partial tandem duplications (KMT2A-PTD), and dual alterations (KMT2A-r/PTD). In this study of 125 patients, these subgroups exhibited distinct molecular profiles: KMT2A-r cases were enriched in RAS pathway mutations, whereas KMT2A-PTD showed a higher burden of epigenetic alterations. Although overall survival (OS) and event-free survival (EFS) did not differ significantly between subgroups, prognosis was strongly influenced by fusion partners. MLLT3/ELL-rearranged cases showed superior outcomes, but concurrent KMT2A-PTD abrogated this survival advantage, AFDN and other fusions showed poor outcomes. We therefore propose a revised three-tier risk model integrating fusion partner and PTD status, which significantly stratified patient outcomes. The intermediate-risk group (MLLT3/ELL without PTD) had a 3-year OS of 78.1%, compared to 50.5% in the high-risk group (all PTD), and 34.9% in the very high-risk group (other KMT2A-r) (P = 0.044). For EFS, the rates were 71.0%, 40.1%, and 24.9%, respectively (P = 0.003). Allogeneic hematopoietic cell transplantation significantly improved survival, with 3-year OS rates of 75.2% in transplant recipients versus 22.5% in non-transplanted patients (P < 0.001), particularly in high-risk groups and when performed in first complete remission. These findings support the use of molecularly guided, risk-adapted therapy in KMT2A-altered AML.